by admin | Feb 10, 2021 | Pharmaceutical Litigation, Singulair
In March 2020, FDA added stronger warnings about the potential psychiatric side effects of Singulair, an asthma and allergy drug. Studies have linked the medication to reports of depression, suicidal behavior, and other mental health risks. About Singulair Singulair... 
by michael | May 13, 2020 | Singulair
In March 2020, FDA has added a black box warning of mental illness to the popular asthma medication, Singulair. The FDA has received countless reports of potential psychiatric side effects including depression, suicidal behavior, and other mental health risks. About...
Recent Comments